Upload
ashutoshrv
View
227
Download
0
Embed Size (px)
Citation preview
8/6/2019 Eighth Bio Spectrum June 10
1/15
8/6/2019 Eighth Bio Spectrum June 10
2/15
A CybrMdia Pblicatio | biospctrmidia.com | June 2010 | BIOSPECTRUM | 19
Biotech Directory
2009-10
BioSpectrumconductedthissurveyjointlywiththeAssociationofBiotechnologyLedEnterprises(ABLE).BioSpectrumandABLEhavejointlybeendoingthis
exercisesince2003.Adetailedquestionnaire(surveyform)wassenttoover150companiestocapturetheneededinformationfortheanalysis.ThiswasdoneduringApril-May2010.Companiessharedinformationwithustotheextentitwaspossiblebythemabouttheircompaniesandtheindustry.
Therevenuesconsideredfortheanalysisarebiotechproductssalesandservicefigures.Inseveralcases,whererevenuefigureswerenotavailableestimateswerearrivedtalkingtoindustryexperts.Thesearedenoted(*)asBioSpectrumestimates.
ThisyearinthelistofTop20biotechcompanies,serv-icescompaniesinthedrugdiscoveryspacehavebeentakenintoaccount,whilediagnosticscompanieshavenotbeenconsidered.Anoveralllistingofcompanies(Page110&112)byrevenuehasbeendoneforyourreferenceincludingdiagnosticcompanies.
Biotechsuppliersrevenuesarenotconsideredaspartofthebiotechdefinition.
BioPharmaincludedproductsmadebyfermentation/animalcellculture(notanimalextracts)andplantcellculture(notplantextracts).
TheBioAgrisegmentanalysishasincludedonlytheGMseedsandmolecularmarkersandrelatedproducts.So,thehybridseedsbusinessisnotapartoftheagri-busi-
nesssalesvalues. Foralltherankingpurposes,wehavetakenthebiotech
businessonlyintoconsideration.WhereverTURNOVERismentioneditmeans,salesturnoverfrombiotech.Therefore,turnoverwherevermentionedisnotneces-sarilythetotalsalesturnoverofthecompany.
SURVEY & RANKING METHODOLOGY
IndustryOverviewIndustryOverview
BioSpectrumABLE Biotech Industry Survey 2010
8/6/2019 Eighth Bio Spectrum June 10
3/15
20 | BIOSPECTRUM | June 2010 | biospctrmidia.com | A CybrMdia Pblicatio
Biotech Directory
2002-03
1790
75235
110 135
80238
130275
2752
3570
100320
330425
4708
120375
598
720
5973
145
395
926
11026899
190
410
1201
1572
7883
220
478
1494
2062
8829
231
564
1936
2639
2003-04 2004-05 2005-06 2006-07 2007-08 2008-09 2009-10
INDIA BIOTECH INDUSTRY 2002-10
FY
BioInformatics
BioIndustrial
BioAgri
BioServices
BioPharma
TotalRevenue
Total-2345
Total-3475
Total-12137
Total-14199.17
Total-10272
Total-8541
Total-6521
Total-4745
0
2500
5000
7500
10000
12500
15000
India biotech
$3 bn
Size
Registers Rs 14,199 crGrows17%recovers
Industry Overview
BioSpectrumABLE Biotech Industry Survey 2010
*AllfiguresinRs.Croreunlessindicatedotherwise
8/6/2019 Eighth Bio Spectrum June 10
4/15
A CybrMdia Pblicatio | biospctrmidia.com | June 2010 | BIOSPECTRUM | 21
Biotech Directory
Biotech Industry Exports vs Domestic 2009-10
Segment Exports Domestic Total % shareExports
% shareDomestic
Biopharma 4767.66 4061.34 8829 54 46
BioServices 2507.05 131.95 2639 95 5
BioAgri 58.08 1877.92 1936 3 97
BioIndustrial 124.08 439.92 564 22 78
BioInformatics 73.92 157.08 231 32 68
Total 7530.79 6668.21 14199 53.04 46.96
Biotech Industry Exports vs Domestic 2008-09
Segment Exports Domestic Total % shareExports
% shareDomestic
Biopharma 4868 3015 7883 62 38
BioServices 1964 98 2062 95 5
BioAgri 61 1433 1494 4 96
BioIndustrial 89 389 478 11 89
BioInformatics 50 170 220 23 77
Total 7152 4985 12137 59 41
BioAgri
grows at37%
28%BioServicesfollows at
In dollar terms, the industry
crossed$3billioninFY2009-10
growing23% overa flatgrowth
ofFY2008-09.
Exportsaccountedfor53%share
in the overall revenue and reg-istered a growth of5%overFY
2008-09.
Domestic business claimed 47%
shareintheoverallrevenueand
registeredagrowthof34%over
FY2008-09.
Industry Overview
*AllfiguresinRs.Croreunlessindicatedotherwise
BioSpectrumABLE Biotech Industry Survey 2010
8/6/2019 Eighth Bio Spectrum June 10
5/15
24 | BIOSPECTRUM | June 2010 | biospctrmidia.com | A CybrMdia Pblicatio
Biotech Directory
61.71 18.78
13.93
3.95
1.63
Biotech Industry Segment Revenue % Share
% Share 2010
64.9516.99
12.31
3.941.81
% Share 2009
BioPharma
BioServices
BioAgri
BioIndustrial
BioInformatics
40
35
30
25
20
15
10
0
Revenueshare%changeover2007-2008
Revenueshare%changeover2008-2009
Biotech Industry SegmentRevenue % Change
Biopharma BioServicesBioAgriBioIndustrialBioInformatics
Segment 2007-08 2008-09 2009-10 %ChangeOver2007-08
%ChangeOver2008-09
Biopharma 6899 7883 8829 14 12
BioServices 1572 2062 2639 31 28
BioAgri 1201 1413 1936 23 37
BioIndustrial 410 478 564 16 18
BioInformatics 190 220 231 16 5
Total 10272 12137 14199 100 100
Biocon back
to No. 1 slot
Company Highlights
Industry Overview
BioSpectrumABLE Biotech Industry Survey 2010
Total revenue Rs 14,199 Crore Total revenue Rs 12,137 Crore
*AllfiguresinRs.Croreunlessindicatedotherwise
Top20companiescontributed52%ofthetotalrevenue.
Thesecompaniesgrewatanaveragegrowthrateofover22%
whiletheindustrygrowthratestoodat17%inFY2009-10.
SerumInstituteofIndiaslippedtoNo.2onaccountoflossof
somekeycontracts.
ShanthaBiotechistheonlyTop20revenuecompanytohaveshowcasedagrowthover30%percent.
TotalrevenuesofTop20homegrowncompanieshavegrown
by25%overFY2008-09.
Fastestgrowing20companiescontributed20%oftheoverall
industryrevenueofRs14199.17crore.Thesehavegrownat
anaveragerateofover150%.
Thepackoffastestgrowingcompaniesintheregionisledby
CROs,whicharegrowingfromaverysmallbaseoflessthan
Rs30crore.
The fastest growing 20 companies in the region are all
belowRs150crorewiththeexceptionofShanthaBiotechatRs334.23crore.
8/6/2019 Eighth Bio Spectrum June 10
6/15
A CybrMdia Pblicatio | biospctrmidia.com | June 2010 | BIOSPECTRUM | 25
Biotech Directory
RevenueRank2010
Company2009-10(Revenue
inRsCr)2008-09(Revenue
inRsCr)2007-08(Revenue
inRsCr)%Change
Over2007-08%ChangeOver
2008-09
1 Biocon 1180 912.34 876.93 4.04 29.34
2 Serum Institute of India* 850 1114.00 987.00 12.87 -23.70
3 Panacea Biotec 703.19 597.14 681.16 -12.33 17.76
4 Nuziveedu Seeds 476.86 449.58 291.88 54.03 6.07
5 Reliance Life Sciences* 450
6 Quintiles* 375
7 Rasi Seeds 358.78 375.59 293.68 27.89 -4.48
8 NovoNordisk* 342 330.00 260.00 26.92 3.64
9 Shantha Biotech 334.23 247.00 150.00 64.67 35.32
10 Mahyco 312 211.12 135.86 55.40 47.78
11 Indian Immunologicals 272.87 231.46 172.70 34.02 17.89
12 Bharat Biotech 271.66 241.05 83.44 188.89 12.70
13 Novozymes South Asia* 268 250.00 225.00 11.11 7.2014 Monsanto* 255 345.00 -26.09
15 Syngene International 252 224.60 175.50 27.98 12.20
16 Jubilant Organosys 249.3 242.00 159.00 52.20 3.02
17 Eli Lilly 187 164.00 149.00 10.07 13.85
18 Bharat Serums 175 140.00 140.00 0.00 25.00
19 Haffkine Biopharma 168.98 88.61 -100.00
20 Siro Clinpharm 150 280.00 -46.43
Top 20 Biotech Companies by Revenue (2009-10)
Industry Overview
BioSpectrumABLE Biotech Industry Survey 2010
Revenue
Rank2010Company
2009-10(Revenue
inRsCr)
2008-09(Revenue
inRsCr)
2007-08(Revenue
inRsCr)
%Change
Over2007-08
%ChangeOver
2008-091 Stempeutics 17.19 1.06 1.42 -25.35 1521.70
2LambdaTherapeuticResearch*
145 30.00 383.33
3MaxNeemanInternational
40 15.00 10.00 50.00 166.67
4 ConcordBiotech 111.7 52.13 53.13 -1.88 114.27
5 KrishidhanSeeds 133.23 63.25 47.70 32.60 110.64
6 AventisPharma 68.34 36.00 105.00 -65.71 89.83
7 Maps(India)* 45 25.00 80.00
8 NathSeeds 85 48.50 62.00 -21.77 75.26
9 AnthemBiosciences 53 32.34 63.88
10 SuvenLifeSciences 33.5 21.03 27.70 -24.08 59.30
11 CadilaHealthcare 147.48 93.70 77.04 21.63 57.40
12 DrReddysLaboratories 62.5 40.00 34.00 17.65 56.25
13 Mahyco* 312 211.12 135.86 55.40 47.78
14 GlaxoSmithKline 123.34 83.48 80.65 3.51 47.75
15 Wyeth* 53 37.00 43.24
16 AdvancedEnzymes 121 88.60 69.30 27.85 36.57
17 AnkurSeeds 109.5 80.35 55.73 44.18 36.28
18 ShanthaBiotech 334.23 247.00 150.00 64.67 35.32
19 JKAgrigenetics* 35 26.00 46.00 -43.48 34.6220 ABLBiotechnologies 14.81 11.31 20.03 -43.53 30.95
Top 20 Biotech Companies by Growth (2009-10)
AllfiguresinRs.Croreunlessindicatedotherwise*BioSpectrumestimates
8/6/2019 Eighth Bio Spectrum June 10
7/15
28 | BIOSPECTRUM | June 2010 | biospctrmidia.com | A CybrMdia Pblicatio
Biotech Directory
Top 20 Homegrown Biotech Companies by Revenue (2009-10)Revenue
Rank2010Company
2009-10(RevenueinRsCr)
2008-09(Rev-enueinRsCr)
2007-08(Rev-enueinRsCr)
%ChangeOver2007-08
%ChangeOver2008-09
1 Biocon 1180 912.34 876.93 4.04 29.34
2SerumInstituteofIndia*
850 1114.00 987.00 12.87 -23.70
3 PanaceaBiotec 703.19 597.14 681.16 -12.33 17.76
4 NuziveeduSeeds 476.86 449.58 291.88 54.03 6.07
5 RelianceLifeSciences* 450
6 RasiSeeds 358.78 375.59 293.68 27.89 -4.48
7 ShanthaBiotech 334.23 247.00 150.00 64.67 35.32
8 IndianImmunologicals 272.87 231.46 172.70 34.02 17.89
9 BharatBiotech 271.66 241.05 83.44 188.89 12.70
10 SyngeneInternational 252 224.60 175.50 27.98 12.2011 JubilantOrganosys 249.3 242.00 159.00 52.20 3.02
12 BharatSerums 175 140.00 140.00 0.00 25.00
13 HaffkineBiopharma 168.98 88.61 -100.00
14 SiroClinpharm 150 280.00 -46.43
15 CadilaHealthcare 147.48 93.70 77.04 21.63 57.40
16LambdaTherapeuticResearch*
145 30.00 383.33
17 KrishidhanSeeds 133.23 63.25 47.70 32.60 110.64
18 IntervetIndia* 121.6
19 AdvancedEnzymes 121 88.60 69.30 27.85 36.5720 IntasBiopharma 115 89.27 47.29 88.77 28.82
WesternclustercontinuestodominateIndiasbiotechindustrywith46%
shareintheoverallrevenuesofRs14,199crore.The137companiesinthe
regionbetweenthemselvesclockedRs6,631croreinFY2009-10increas-
ingtheregionsshareintheoverallrevenuesby3%overFY2008-09,thus
gainingaleadof6%overSouth,itsclosecompetitorforthetopslot.
TheIndianBioPharmamarketcomprisingprimarilyofvaccines,thera-
peuticdrugs,insulin,animalbiologicals,statinsanddiagnosticsin2009-2010,continued tograbthe largest shareof the totalbiotech industry
revenuesofoverRs14,199crore.ItcontributedRs8829crore,accounting
for62%revenueshare.
IntermsofPEfundinginlifesciences,in2009-10anestimated$200mil-
lionwas investedin the Indiabiotechindustrywith40%ofthisbeing
pumpedintotheBioPharmasegment.WithinBioPharmavaccines,di-
agnosticsandmedicaldeviceshavebeenthelucrativesectorsformostof
theIndianPEinvestors.InvestorsarealsobullishaboutmAbsspace.
ThegovernmentofIndiathroughDepartmentofBiotechnology(DBT)al-
locatedRs902croreforvariousprojectsin2009-10.Thisallocationfor
2010-11isRs1,200crore.Thecollaborationsandpublic-privatepartner-
shipsinthebiotechindustryareontherise.TheinitiativesfromDBT
SmallBusinessInnovationResearch Initiative (SBIRI),andtheBill&
MelindaGatesFoundation are some of the examplesof collaborations
betweengovernmentandindustry.DBThasalsotiedupwithUK-based
Wellcome Trust to enhance cutting-edge biomedical research in India.
Thetrusthasallocated30millionpoundsforaperiodoffiveyearstofund
R&DresearchinIndia.
ItwastheYearofRecovery
fortheindustrymarkedby
consolidation,collaborations
andaspateofdealsbetween
pharmaandbiotechs.The
secondhalfof2009sawmostcompanies,primarily
biopharmacompanies,
postinghealthiertopline
andmargins.TheShantha
Biotech-SanofiPasteurdeal
in2009becameadefining
pointintheindustrywith
Shanthaselling-outateight
timesitsvaluationofRs
3,475crore($770million).
ThetrendofMNCsscouting
forandacquiringdomestic
playerswithastrongfoothold
inthemarketpickedup
steamafterthis.
Industry Overview
AllfiguresinRs.Croreunlessindicatedotherwise
BioSpectrumABLE Biotech Industry Survey 2010
*BioSpectrumestimates
8/6/2019 Eighth Bio Spectrum June 10
8/15
30 | BIOSPECTRUM | June 2010 | biospctrmidia.com | A CybrMdia Pblicatio
Biotech Directory
Western cluster continues to
dominate Indias biotech
industry with 46 percent
share in the overall revenues of Rs
14,199 crore. The 137 companies
in the region between themselves
clocked Rs 6,631 crore in FY 2009-10
increasing the regions share in the
overall revenues by 3 percent over
FY 2008-09, thus gaining a lead of 6
percent over South, its close competi-
tor for the top slot.
Not just that, this year, Mumbai
outpaced Bangalore to become Indias
Top Biotech City with a small margin
of about Rs 200 crore in terms of rev-
enue. Besides, Gujarats share in the
total revenue has grown by almost 50
percent as compared to its revenues
of Rs 755 crore in 2008-09. In Ma-
harashtra , Punes contribution wentdown as the leading company of the
region Serum Institute of India suf-
fered contract set backs.
So, has South regions position vis-
a-via West worsened since last year?
Not really. Given the policy and in-
frastructure push the situation next
year could even see a dramatic shift.
South continues to remain Indias
largest Biotech cluster in terms of
the number of companies. In 2009-
10, it added another 9 companies
highest in the country. The region
has 172 biotech companies (West has
137 companies), which churned out
Rs 5537.68 crore in revenues in FY
2009-10 making up 39 percent of the
overall revenues.
In the South region, Karnataka
state government has proposed to set
up five new biotech parks and has in-
vested Rs 1,100 crore towards new in-
itiatives in 2009-10. Another biotechhub Andhra Pradesh is also setting
up a MedTech Valley, a world-class
Top Companies in NorthCompany 2009-2010 (Revenue in
Rs Cr)% Share in
Region% Share of Total
Biotech
Panacea Biotec 703.19 34.63 4.95
Jubilant Organosys 249.30 12.28 1.76
Eli Lilly 186.72 9.20 1.32
Top 3 North 1139.21 56.11 8.02
Total North 2030.48 14.30
Top Companies in SouthCompany 2009-2010 (Revenue
in Rs Cr)% Share in
Region% Share of Total
Biotech
Biocon 1180 21.31 8.31
Nuziveedu Seeds 476.86 8.61 3.36
Rasi Seeds 358.78 6.48 2.53
NovoNordisk* 342 6.18 2.41
Shantha Biotech 334.23 6.04 2.35
Indian Immunologicals 272.87 4.93 1.92
Bharat Biotech 271.66 4.91 1.91
Novozymes South Asia 268 4.84 1.89Syngene International 252 4.55 1.77
Ecron Acunova 97 1.75 0.68
Top 10 South 3853.40 69.59 27.14
Total South 5537.68 39.00
Top Companies in WestCompany 2009-2010 (Revenue in
Rs Cr)% Share in
Region% Share of
Total Biotech
Serum Institute of India* 850 12.82 5.99
Reliance Life Sciences* 450 6.79 3.17
Quintiles* 375 5.66 2.64
Mahyco 312 4.71 2.20
Monsanto* 255 3.85 1.8
Bharat Serums 175 2.64 1.23
Haffkine Biopharma 168.98 2.55 1.19
Siro Clinpharm 150 2.26 1.06
Cadila Healthcare 147.48 2.22 1.04
Lambda Therapeutic Research* 145 2.19 1.02
Ajeet Seeds* 103 1.55 0.73
Top 10 West 2883.46 43.48 20.31
Total West 6631.01 46.70
BioCluster
BioSpectrumABLE Biotech Industry Survey 2010
West retains No position1The region has improved its lead over South by 6%
Mumbai outpaces Bangalore, becomes Indias Top Biotech City
All figures in Rs. Crore unless indicated otherwise*BioSpectrum estimates
8/6/2019 Eighth Bio Spectrum June 10
9/15
32 | BIOSPECTRUM | June 2010 | biospctrmidia.com | A CybrMdia Pblicatio
Biotech Directory
0
2500
5000
7500
10000
12500
15000
2002-03 2004-05 2005-06
Top Biotech Clusters & Cities (2009-10)cluster for manufacturing medical
devices and equipment near Genome
Valley at Shameerpet in Hyderabad.
The state government will provide
1,200 acres of land for the project.
The project will be executed via apublic-private partnership model.
Kerala has also taken steps to jump
on the biotech bandwagon. Kerala
State Industrial Development Corp
(KSIDC) has announced that it will
set up a state-of-the-art life science
park at Thiruvananthapuram at an
estimated cost of Rs 300 crore. The
project that will come up in 260 acres
at Thonnakkal, would be developed
under public-private partnership
model. The park will house an incu-
bation center, a technology develop-
ment center, biotechnology compa-
2003-04
BioCluster
BioSpectrumABLE Biotech Industry Survey 2010
West
South
North
Total
Top 10 companies in the West have 43%
share in the region.
Serum Institute of India
(Rs 850 crore), the regions No 1 company
makes up for about 13% of the regions
revenue and contributes 6% to the overall
industry revenue.
Biotech Revenue Cluster Trend (2002-10)
8/6/2019 Eighth Bio Spectrum June 10
10/15
A CybrMdia Pblicatio | biospctrmidia.com | June 2010 | BIOSPECTRUM | 33
Biotech Directory
2006-07 2007-08 2008-09
nies, drug discovery companies, pure
play firms and also contract research
outsourcing units.
Looking ahead, year 2010-15 will see
some shifts, specializations and emer-
gence of clear patterns. During thisperiod many of the mega initiatives
are likely to take off and have the po-
tential to be a leap of sorts that can
build a virtuous cycle for the region.
NCR at No 4
The Northern biocluster National
Capital Region (NCR) has the Top 3
companies contributing 56 percent of
the revenues and about 15 percent
of the overall industry revenue. This
cluster is better known for its re-
search institutes and of course, gov-
ernment bodies.
More recently, the development
of 200 acre Health Biotech Science
Cluster (HBSC) at Faridabad is un-
derway. A multidisciplinary approach
to education and research, this Bio-
tech cluster would comprise Transla-tional Health Science & Technology
Institute (THSTI), Regional Center
for Biotechnology (RCB) Center for
Vaccinology, Molecular Medicine
Center, Center for Diagnostics, Bio-
tech Park,), Center for Health Sci-
ence Technology, Center for Platform
Technologies, UNESCO Center, Incu-
bator and a Center for Animal Model
for Clinical Advances. As a first step,
a temporary THSTI lab was recently
inaugurated at Gurgaon. This would
be shifted to the main site at Farida-
bad in two-three years after the in-
frastructure is ready.
Besides, there is the biotech park
at Lucknow offering a very good plat-
form for the small and medium bio-
tech companies to do research, col-
laborate and expand their business.The Biotech Parks at three locations
Sitapura-Jaipur and Chopanki,
Bhiwadi (Alwar), and Borandi, Ra-
jasthan have been initiated by Rajas-
than State industrial Development
& Investment Corporation (RIICO).
Then, there is the proposed bioclus-
ter at Mohali (Punjab), upcoming
biotech park at Chandigarh (Pun-
jab) and another one at Nalagarh
in Himachal Pradesh all this is
expected to provide the much needed
boost to the biotech companies in the
North region.
BioCluster
BioSpectrumABLE Biotech Industry Survey 2010
West is also base for top bioagri companies such as
Monsanto, Mahyco and Ajeet Seeds.
MNCs like GlaxoSmithKline, Roche, Aventis Pharma,
Wyeth, Quintiles are also headquartered in the region.
Four of Indias top 10 services companies (CROs) are
also based out of West, including the No 1 CRO in the
Indian industry Quintiles India (Rs 375 crore)
*All figures in Rs. Crore unless indicated otherwise
2009-10
8/6/2019 Eighth Bio Spectrum June 10
11/15
36 | BIOSPECTRUM | June 2010 | biospctrmidia.com | A CybrMdia Pblicatio
Biotech Directory
Top 20 BioPharma Companies by Revenue (2009-10)
BioPharma to grow over
10%for next
5years
BioPharma clocks Rs 8,829 crore in revenues
It accounted for 62% of the total revenue and grewby 12% over FY 2008-09
The Top 20 BioPharma companies contributed close
to Rs 6000 crore
The Indian BioPharma market
comprising primarily of vac-
cines, therapeutic drugs, insu-
lin, animal biologicals, statins and
diagnostics in 2009-2010, continued
to grab the largest share of the total
biotech industry revenues of over Rs
14,199 crore. It contributed Rs 8,829
crore, accounting for 62 percent mar-
ket share.
Vaccines had the largest pie with
an estimated sales of Rs 2,180 crore
over last years figure of Rs 2,000
crore. The vaccine segmenthuman
as well as animal vaccinesaccount-
ed for 50-60 percent of the total BioP-
harma market. Total estimated sales
from the human vaccine business
stood at Rs 1,750 crore over the 2008-
2009 figure of Rs 1,550 crore. Domes-
tic sales of human vaccines just about
crossed Rs 1,000 crore. In FY 2008-09
this figure stood at Rs 900 crore. Ex-
port sales is estimated to have gener-
ated Rs 750 crore, as compared to Rs
650 crore in FY 2008-09. Animal Vac-
cines registered a marginal decline
Revenue
Rank 2010
Company 2009-10 (Revenue in Rs Cr) 2008-09 (Revenue in Rs Cr) % Change Over
2008-091 Biocon 1180 912.34 29.34
2 Serum Institute of India* 850 1114.00 -23.7
3 Panacea Biotec 703.19 597.14 17.76
4 Reliance Life Sciences* 450
5 NovoNordisk* 342 330.00 3.64
6 Shantha Biotech 334.23 247.00 35.32
7 Indian Immunologicals 272.87 231.46 17.89
8 Bharat Biotech 271.66 241.05 12.7
9 Eli Lilly 187 164.00 13.85
10 Bharat Serums 175 140.00 25
11 Haffkine Biopharma 168.98
12 Cadila Healthcare 147.48 93.70 57.4
13 GlaxoSmithKline 123.34 83.48 47.75
14 Intervet India 121.6
15 Intas Biopharma 115 89.27 28.82
16 Themis Medicare 112.12 97.50 14.99
17 Concord Biotech 111.7 52.13 114.27
18 Venkateshwara Hatcheries* 90
19 Aventis Pharma 68.34 36.00 89.8320 Dr Reddys Laboratories 62.5 40.00 56.25
Segment Overview
BioSpectrumABLE Biotech Industry Survey 2010
All figures in Rs. Crore unless indicated otherwise* BioSpectrum estimates
8/6/2019 Eighth Bio Spectrum June 10
12/15
38 | BIOSPECTRUM | June 2010 | biospctrmidia.com | A CybrMdia Pblicatio
Biotech Directory
with sales of Rs 430 crore over last years figure of Rs
450 crore. In animal vaccines, poultry vaccines clocked
Rs 220 crore, cattle and sheep vaccines registered Rs 210
crore.
The vaccine market will continue to drive the growth
of the biopharma segment growing in the range of 10-13percent in the next 5 years. The factors that will drive
this include education and awareness about disease pre-
vention, increase in disposable income and participation
by government.
The market will clearly shift to combination vaccinessuch as Pentavalent vaccines. Domestic players such as
Bharat Biotech and Shantha Biotech have already re-
ceived massive orders from the Government of India for
immunization programmes in Himachal Pradesh, Kerala,
Tamil Nadu, Jammu and Kashmir and Karnataka. There
is going to be a change from largely whole-cell pertusis
-based combos to acellular-based combos in the coming
years. Newer vaccines like Pneumo conj, Meninge Conj
and HPV would drive the market growth in paediatric
and adolescent segment, while Flu will continue to be a
big driver in the adult market segment.
A noteworthy product launched during 2009-2010 was
Shanthas ShancholIndias first oral vaccine to pro-
tect against cholera. Shanchol is a bivalent inactivated-
whole-cell oral cholera vaccine developed by Shantha in
collaboration with the International Vaccine Institute
(IVI), Seoul, Korea.
Driven by a rise in chronic diseases and investments inthe healthcare infrastructure, diagnostics and thera-peutics business also had a positive impact on the industry.
The diagnostic market is estimated to be at Rs 2,000 crore
with molecular diagnostic market share at $300 million in
FY 2009-2010. This accounts for 20-22 percent share of thetotal BioPharma market. A highly competitive segment,
the market currently is growing at 15-20 percent with a
50:50 revenue share split between MNCs and homegrown
companies. Major MNC companies in the diagnostic mar-
ket include Roche, Siemens (which has acquired Bayer Di-
agnostics) and Abbott while homegrown names in the top
league include Tulip Group, Transasia Biomedicals, RFCL(Diagnova), Span Diagnostics and Trivitron. This growth
is driven from the gradual acceptance of the concept of pre-
ventive and personalized medicine. The therapeutics mar-
ket claimed 15 percent of market share in FY 2009-2010
with the cancer therapeutics sales clocking Rs 311 crore.
Companies in the segment are now moving towards nov-
el targeted therapies and supportive care products. Can-
cer therapeutics is a lucrative business for many Indian
companies because of high unmet needs, high prices of
innovator drugs, increase of awareness and affordability.
These homegrown players will play a pivotal role in re-
ducing the price points of important cancer drugs.
The market size of Oral Diabetes Drugs is estimated to
be Rs 1,550 crore and market size of Insulin (including
analogs) is approximately Rs 612 crore. The large mar-
ket size is reflective of India emerging as the diabetes
capital of the world. Between 1995 and 2005 the number
of diabetic patients doubled from 20 million to 40 mil-
lion and this is projected to grow to 70 million patients
by 2025. In Insulin (including Analog) segment, Novo
Nordisk is the market leader with over 50 percent mar-
ket share while Eli Lilly has 22 percent market share.
Analogs which currently contribute 27 percent in value(8 percent in volume) are the fastest growing segment
(with 2007-09 CAGR of 32 percent) in value. Within in-
sulin market, novel delivery devices would be the growth
drivers in the coming years.
Biogenerics segment in the near term will be a keygrowth driver for Indian players especially with theUS set to establish a biogenerics (biosimilars) pathway
by 2013. In India, Erythropoietin (EPO) clocked a sales
of Rs 10 lakh ($22,000), c-GSFRs 5 lakh ($11000), in-
terferonRs 10 lakh $22000 and streptokinase Rs 7 lakh
($16000). These products are been sold at price discounts
of upto almost 85 percent of its innovator drug thus mak-
ing them affordable to the masses. Currently, Dr Reddys
Labs, Ranbaxy, Biocon, Shantha Biotechnics and Intas
Biopharmaceuticals are actively involved in the space.
There are around 25 Indian players with over 50 prod-
ucts already being sold in the Indian market and some
being sold in the unregulated markets as well. Other
prominent companies that have started initiatives in the
field include Glenmark, Cipla and Lupin Pharma. Last
year, Cipla entered into a 50:50 joint venture (JV) with a
Chinese company for biosimilars. The JV would be called
Biomab and Cipla is likely to bring out Biomabs firstproduct later this year.
Segment Overview
BioSpectrumABLE Biotech Industry Survey 2010
The vaccine market will continue to
drive the growth of the biopharma
segment growing in the range of
10-13% in the next 5 years
8/6/2019 Eighth Bio Spectrum June 10
13/15
40 | BIOSPECTRUM | June 2010 | biospctrmidia.com | A CybrMdia Pblicatio
Biotech Directory
BioServices segment registered
a growth of 28 percent in
2009-10 over last years total
segment revenue of Rs 2,062 crore.
The 3 percent drop in growth from a
31 percent of 2008-09 was primarily
due the currency fluctuations in FY
2009-10. Exports continue to domi-
nate this segment accounting for over
90 percent of the total revenues.
In this segment, accounting for 19
percent of overall revenue, compa-
nies such as Lambda Therapeutic
Research, MaxNeeman and Anthem
Biosciences have done exceedingly
well in FY 2009-10 with Lambda and
MaxNeeman growing well over 100
percent and Anthem Biosciences atover 60 percent. The Top 10 CROs
make up 60 percent of the total seg-
ment revenue of Rs 2,639 crore.
In the last three-to-five years, many
companies have set up contract re-
search and clinical research services
operations in India. Considering the
potential opportunity and fast clip
market growth, the number of com-
panies in this segment will continue
to grow faster than the industry aver-
age in the next two years as well.
The segment is growing on account
of the growing requirements of the
multinational companies that are
looking at India as an outsourcing
destination with high-skill, low cost
advantage. Besides, due to business
model evolutions driven by market
forces, even the domestic companies
are outsourcing various portions of
the drug discovery chain.
However, the competition in the
segment is growing to be intense im-
pacting bottomlines adversely. Thefact that all new companies are now
born global is adding to this compe-
tition. SIRO Clinpharm having pres-
ence in India, Western & Central
Eastern Europe, and US has now
entered into an alliance with Dream-
CIS Inc., a leading CRO based out of
Top 10 Services Companies by Revenue (2009-10)Rank
2010
Company 2009-10 (Revenue
in Rs Cr)
2008-09 (Revenue
in Rs Cr)
% Change
Over 2008-091 Quintiles India* 375 --- ---
2 Syngene International 252 224.60 12.2
3 Jubilant Organosys 249.3 242.00 3.02
4 Siro Clinpharm 150 280.00 -46.43
5 Lambda Therapeuticresearch*
145 30.00 383.33
6 Veeda Clinpharm 110 --- ---
7 Ecron Acunova 97
8 Vimta Labs 88.42 81.60 8.36
9 Anthem Biosciences 53 32.34 63.88
10 Max NeemanInternational
40 15.00 166.67
Seoul in South Korea. The company
has also signed an agreement with Virginia Contract Research Organi-
zation (VCRO), a Taiwan-based CRO
to offer a range of services to Taiwan
companies. And, it is not just Asia Pa-
cific market that the company is look-
ing at. SIRO is expanding operations
in the developed markets like USA
and Europe as well. It has entered an
alliance with Advanced Clinical Trial
Solutions (ACT Solutions), Fleming-
ton, NJ, USA.
Syngene International, a subsidi-
ary of Biocon Group, has partnered
with Sapient Discovery, a US-based
biotechnology company. Both the
companies intend to provide a highly
integrated platform for structure-
based drug discovery. It also signed a
pact with another US company, Endo
Pharma, to jointly discover and de-
velop novel biological drug molecules
to fight cancer.
Bangalore-based Ecron Acunovahas tied-up with a Japanese CRO
and expects this alliance to trigger
a trend and set off 40-50 clinical tri-
als between India and Japan in the
next two-to-three years. Japan is the
second biggest pharma market after
the US. This apart, the Indo-German
clinical research major with its estab-
lished presence in India and Europe
is scouting for more market share in
clinical research in these countries
and other parts of the globe.
Veeda Clinical Research, which
has completed five years of existence
in January 2010, has opened its of-
fice in South East Asia by signing
a collaborative agreement with the
Malaysian Ministry Health to open
a Phase I and Early Clinical Develop-
ment Unit in the Ampang Hospital in
Kuala Lumpur.
India services industry is, decid-
edly, set to take the collaborationgrowth highway.
CROs take the growth highway
BioServices registers 28% growth withrevenue of Rs 2,639 crore
Top 10 CROs make up 60% of the total
segment revenue
Segment Overview
All figures in Rs. Crore unless indicated otherwise
BioSpectrumABLE Biotech Industry Survey 2010
* BioSpectrum estimates
8/6/2019 Eighth Bio Spectrum June 10
14/15
42 | BIOSPECTRUM | June 2010 | biospctrmidia.com | A CybrMdia Pblicatio
Biotech Directory
Agri biotech is the third largest
contributor to Indian biotech
industry in FY 2009-2010
with a total segment turnover of Rs
1,936 crore, accounting for almost 14
percent of the total biotech revenues.
Registering a growth of 37 percent
over last year, BioAgri emerged the
industrys fastest growing segment.
The fact that BioServices segment
dominated by exports faced minor
setbacks on account of currency fluc-
tuations helped BioAgri gain lead.
In FY 2008-09 BioServices with a
growth of 31 percent was the fastest
growing industry segment.
India is the fourth largest country
in the world with almost 8.4 million
hectares of area under Bt cotton. On
Region Production
North 600 kg per hectare
West 516 kg per hectare
Central 472 kg per hectare
South 595 kg per hectare
one side the area under Bt cotton has
been on increasing, on the other side
the prices for Bt seeds packets has
been slightly on decline. This decline
is because of governments interven-
tion and more companies launching
different technologies for producing
Bt seeds.
The number of companies sell-
ing Bt cotton seeds in India has in-
creased dramatically over the last
eight years since the first commer-
cialization in 2002. Today, there are
over 30 companies marketing Bt cot-
ton seeds in the country.
Nuziveedu Seeds is the largest sell-
er of Bt cotton seeds. The company
sold 70 lakh packets generating Rs
476.86 crore in revenues. Rasi Seeds
is the second largest contributor withRs 358.78 crore in sales. Nuziveedu
has 25 percent of the market share
while Rasi Seeds is close second with
19 percent market share. Other sig-
nificant players include Ajeet Seeds,
Ankur Seeds selling 12-20 lakh pack-
ets each in FY 2009-10.
Top 10 Agri Companies by Revenue (2009-10)
Rank2010
Company 2009-10 (Rev-enue in Rs Cr)
2008-09 (Revenuein Rs Cr)
% Change Over2008-09
1 Nuziveedu Seeds 476.86 449.58 6.07
2 Rasi Seeds 358.78 375.59 -4.48
3 Mahyco 312 211.12 47.78
4 Monsanto* 255 345.00 -26.09
5 Krishidhan Seeds 133.23 63.25 110.64
6 Ankur Seeds 109.5 80.35 36.28
7 Ajeet Seeds* 103
8 Nath Seeds 85 48.50 75.26
9 JK Agrigenetics* 35 26.00 34.6210 Bayer CropScience* 22.5
A fast clip growth for BioAgri
Segment Overview
BioSpectrumABLE Biotech Industry Survey 2010
All figures in Rs. Crore unless indicated otherwise
A total of 280 lakh packets of seeds
containing 450 grams were sold in
2009, approximately 87 percent be-
ing Bollgard II and 13 percent boll-
gard I. An additional 20 lakh packets
of spurious seeds were estimated to
have been sold illegally to the farm-
ers mainly in Gujarat state. While
in most of the regions, the Bollgard
I and Bollgard II cotton seeds were
priced at Rs 650 and Rs 750 respec-
tively. In North (mainly Punjab,
Haryana and Rajasthan), the pricing
was kept at Rs 759 for Bollgard I and
Rs 925 for Bollgard II.
The Bollgard Bt cotton seeds
were sold in nine states-AndhraPradesh, Tamil Nadu, Karnataka,
Gujarat, Madhya Pradesh, Mahar-
ashtra, Haryana, Punjab, and Ra-
jasthan. Maharashtra leads as the
largest selling state with almost 90
lakh packets sold in the region fol-
lowed by the South (75 lakh packets)
and North (45 lakh packets). The
northern market is mainly held by
Shriram Bioseeds.
A region wise split shows that the
Northern region of India recorded
maximum production of Bt cotton.
An important event of 2009 was
the approval of MLS 9124, developed
indigenously by Metahelix Life Sci-
ences. The product has a synthetic
cry 1C gene. The other development
was the release of two cotton hybrids
namely MH 5124 and MH 5174 ex-
pressing the synthetic cry 1C gene
(MLS 9124).
Notes: *Monsanto royalty has not beentaken into account as segment revenue
Agri biotech grew at 37% in FY 2009-10
There are over 30 companies marketing Bt cotton seeds in IndiaThe segment will grow at an average of 26% in the next 5 years
* BioSpectrum estimates
8/6/2019 Eighth Bio Spectrum June 10
15/15
Biotech Directory
The BioIndustrial market
mainly comprising industrial
enzymes is estimated to be
Rs 564 crore in the year 2009-10 as
against Rs 478 crore in 2008-09. The
segment grew 16 percent in FY 2009-
10. Though the overall enzyme con-
sumption figures of India are com-
paratively low with respect to other
countries and 60-70 percent of domes-
tic demand is imported, the segment
on an average has been growing over
15 percent in the last five years.
In India, the industrial enzyme
consumption is predominantly in the
detergents market (40 percent), fol-
lowed by the starch market (25 per-
cent) . The other important segments
are food and feed, textiles, leather,
pulp and paper. In recent years, en-
zymes have found numerous appli-
cations in the food, pharmaceutical,diagnostic and chemical process-
ing industries. The trend for their
application in almost every sector
BioIndustrial to grow over 15% for next 5 years
BioIndustrial grew 16% in FY 2009-10
70% of the industrial enzyme domestic demand is imported
Top 3 BioInformatics Companies by Revenue (2009-10)Rank2010
Company 2009-10 (Revenuein Rs Cr)
2008-09 (Revenuein Rs Cr)
% ChangeOver 2008-09
1 Ocimum Biosolutions 41.4 47.57 -12.97
2 Strand Life Sciences 35 35.00 0
is on increase.
The leading players in this segment
include Novozymes which has over 50
percent market share followed by Ad-
vanced Enzyme Technologies holding
25-30 percent market share. Other
important players are Maps, Gene-
cor, Lumis and Kerry Biosciences.
Besides, a new entrant Anthem Cel-
lutions, a part of Anthem Biosciences
group has gained significant market
share over a short period of time. Apart from focusing on the local
market, companies like Advanced
Enzyme Technologies are looking at
other markets such as China. Consid-
ering the potential opportunity in the
other markets Advanced Enzyme has
registered good growth in its export
sales.
The Indian companies are report-
ing a good growth, a lot of R&D is
happening in these companies and
new applications are being explored.
Indian companies are looking at
technologies from Europe, China and
Australia.However, with respect to global en-
zyme industry India still needs to do
a lot of catching up.
The smallest segment of the In-
dustry, BioInformatics which
has just about 2 percent seg-
ment share in the overall industry,
has been sluggish in FY 2009-10. It
registered a 5 percent growth over2008-09, clocking Rs 231 crore in rev-
enues last year as compared to Rs
220 crore in FY 2008-09, when it re-
corded a growth of 16 percent.
The pure-play BioInformatics compa-
nies in India include Strand Genom-
ics, Ocimum Biosolutions, SysArris,CytoGenomics and Molecular Connec-
BioInformatics grows at sluggish pace
Segment grows
at 5%Domestic marketcontributes 68% of
BioInformatics revenue
Segment Overview
BioSpectrumABLE Biotech Industry Survey 2010
Top 3 BioIndustrial Companies by Revenue (2009-10)Rank2010
Company 2009-10 (Revenuein Rs Cr)
2008-09 (Revenuein Rs Cr)
% ChangeOver 2008-09
1 Novozymes SouthAsia*
268 250.00 7.2
2 Advanced Enzymes 121 88.60 36.57
All figures in Rs. Crore unless indicated otherwise
*All figures in Rs. Crore unless indicated otherwise
tions. These companies have come out
with products that cater mainly to the
needs of the pharmaceutical and bio-
technology companies. Most of these
companies are small and medium en-
terprises based at locations such asBangalore, Hyderabad, Pune.
*BioSpectrum estimates